Danaher Corporation: A Good Medium Term Bet
Summary: Danaher Corporation’s core sales growth rate is expected to turn positive as 2024 progresses.
Summary: Danaher Corporation’s core sales growth rate is expected to turn positive as 2024 progresses.
Summary: Danaher Corporation stock has surged by 16% since our “Strong Buy” rating in June
Summary: Danaher Corporation, a healthcare/biotech/life sciences supplier, has shown resilience and strength in its core
Summary: Danaher Corporation is a leading player in the life science industry, with strong financial
Summary: Danaher’s annual results show a decrease in sales and EBIT due to the boost
Summary: Despite recent challenges, Danaher remains resilient and strategically positioned for long-term success. Danaher’s 4Q23
Summary: Danaher has undergone a radical transformation from a real estate trust to a leader
Summary: Danaher is my low-risk SWAN stock pick for 2024, with a strong track record
Summary: Danaher Corporation is facing near-term headwinds due to COVID-19-related demand normalization and customer inventory
Summary: Danaher focuses on innovation for steady, high-value recurring revenue, driving financial stability. Aging population,